Therapy Areas: Central Nervous System
MyMD Pharmaceuticals to Collaborate with Bascom Palmer Eye Institute to Study MYMD-1 in Ophthalmic Conditions
13 July 2022 - - US-based pharmaceutical company MyMD Pharmaceuticals, Inc. (NASDAQ: MYMD) has entered into a material transfer agreement with Bascom Palmer Eye Institute of Miami, Florida to collaborate on a pre-clinical study using MYMD-1 as a potential treatment for traumatic optic neuropathy, the company said.

The project is fully funded by Bascom Palmer Eye Institute.

TON is a condition caused by injury to the optic nerve, resulting in partial or complete vision loss.

Visual impairment is usually caused by blunt force trauma to the head. The reported incidence of TON ranges from 1.5% to 4% following head trauma, and each year an estimated 2.8m Americans sustain a traumatic brain injury.

With its 60-year history, Bascom Palmer is in vision research, education, and clinical care.

Bascom Palmer Eye Institute serves as the Department of Ophthalmology for the University of Miami Miller School of Medicine in Miami, Florida.

Its mission is to enhance the quality of life by improving sight, preventing blindness, and advancing ophthalmic knowledge through patient care and research.

Bascom Palmer Eye Institute is ranked the #1 eye hospital in the United States by US News and World Report, an honor it has received 20 times.

The Institute's ophthalmology residency program is ranked best in the US by Doximity, an online professional network for US physicians. 

Originally developed for autoimmune diseases, MYMD-1 is being studied to slow the aging process, prevent sarcopenia and frailty, and extend healthy lifespan.

Because it can cross the blood-brain barrier and gain access to the central nervous system, MYMD-1 is also positioned to be a possible treatment for brain-related disorders.

Its mechanism of action and efficacy in diseases including multiple sclerosis and thyroiditis have been studied through collaborations with several academic institutions.

MYMD-1 has shown effectiveness in pre-clinical and clinical studies in regulating the immune system by performing as a selective inhibitor of tumor necrosis factor-alpha (TNF-α), a driver of chronic inflammation.

Unlike other therapies, MYMD-1 has been shown in these studies to selectively block TNF-α when it becomes overactivated in autoimmune diseases and cytokine storms, but not block it from doing its normal job of being a first responder to any routine type of moderate infection.

MYMD-1's ease of oral dosing is another differentiator compared to currently available TNF-α blockers, all of which require delivery by injection or infusion.

No approved TNF inhibitor has ever been dosed orally. In addition, the drug is not immunosuppressive and has not been shown to cause the serious side effects common with traditional therapies that treat inflammation.

MyMD Pharmaceuticals (NASDAQ: MYMD), a clinical stage pharmaceutical company focused on developing novel therapies for autoimmune and inflammatory conditions, is focused on developing two novel therapeutic platforms that treat the causes of disease rather than only addressing the symptoms. 

MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-α, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines.


Related Headlines